LRMR 投資分析
看多重點：
- 價值≥4
- 股利≥2
分析結論
價值面評分較低，若以價值投資為目標，已經有長期投資部位可能需陸續減碼
LRMR 近期報酬表現
-1.49%
Larimar therapeutics inc
1.41%
同產業平均
0.09%
S&P500
與 LRMR 同產業的標的表現
| 股票代碼 | 公司名稱 | 價值 | 趨勢 | 波段 | 籌碼 | 股利 | 加入追蹤 |
|---|---|---|---|---|---|---|---|
SGMO | Sangamo therapeutics inc | 4 分 | 3 分 | 3 分 | 1 分 | 1 分 | |
MLYS | Mineralys therapeutics inc | - | 4 分 | 4 分 | 2 分 | 1 分 | |
NMRA | Neumora therapeutics inc | - | 2 分 | 2 分 | 2 分 | 1 分 | |
PRME | Prime medicine inc | - | 3 分 | 2 分 | 2 分 | 1 分 | |
FTRE | Fortrea holdings inc | - | 2 分 | 1 分 | 3 分 | 1 分 |
- SGMO Sangamo therapeutics inc價值 4 分趨勢 3 分波段 3 分籌碼 1 分股利 1 分查看更多
LRMR 公司資訊
Larimar Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing treatments for patients suffering from complex rare diseases using its novel cell penetrating peptide (CPP) technology platform. The Company's lead product candidate, nomlabofusp, is a subcutaneously administered, recombinant fusion protein intended to deliver tissue frataxin (FXN), an essential protein, to the mitochondria of patients with Friedreich's ataxia (FA). FA is a rare, progressive, and fatal disease in which patients are unable to produce sufficient FXN due to a genetic abnormality. Its CPP platform, which enables a therapeutic molecule to cross a cell membrane in order to reach intracellular targets, has the potential to enable the treatment of other rare and orphan diseases. It intends to use its proprietary platform to target additional orphan indications characterized by deficiencies in or alterations of intracellular content or activity.